Massachusetts-based AI drug discovery company METiS Therapeutics has launched from stealth with USD 86 million Series A funding, led by PICC PE and China Life, with participation from Sequoia Capital China, Lightspeed, and other investors.
The proceeds will be directed toward further developing the company’s AI drug discovery and delivery platform “AiTEM” and expanding its capabilities to include gene therapy and CRISPR technology. The funds will also be used to advance its pipeline of novel therapeutics, with plans to initiate a human clinical trial of its lead candidate in early 2022.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.